Gary Falk, MD, MS, Professor of Medicine, Director, Center for Esophageal and Swallowing Disorders, Cleveland Clinic, discusses Barrett’s esophagus and its treatment in patients with dysplasia.
Summary:
1. Barrett’s esophagus with high-grade dysplasia has a 50% risk of cancer at 5 years.
2. The first management step is to have histological review of biopsies by a GI pathologist.
Related Videos:
Barrett’s esophagus in the primary care setting
References and Resources
Espinel J, Pinedo E, Rascarachi G. Endoscopic mucosal resection with a multiband ligator for the treatment of Barrett s high-grade dysplasia and early gastric cancer. Rev Esp Enferm Dig. 2009 Jun;101(6):403-407.
Morganstern B, Anandasabapathy S. GERD and Barrett’s esophagus: diagnostic and management strategies in the geriatric population. Geriatrics. 2009 Jul;64(7):9-12.
Dr. Falk has disclosed the following:
Consulting Fees: Wyeth, AstraZeneca, C2 Therapeutics
Contracted Research: Barr, AstraZeneca, Takeda
Treating Barrett’s esophagus in patients with dysplasia
Cancer risk with high grade dysplasia up to 50% at 5 years
August 14, 2009 • Family Medicine, Gastroenterology, Internal Medicine, Oncology, Patient Education, Surgery
